PDA Advanced Therapy Medicinal Products Conference 2025

Team Consulting enjoyed attending PDA Advanced Therapy Medicinal Products Conference 2025, a global event uniting regulators, scientists and industry leaders to explore the evolving landscape of advanced therapies.

Our experts, Laureline Mahe and Joseph Conroy each presented insightful poster sessions. Their sessions included innovation in cell and gene therapy manufacturing and user-centred design for automated bioprocessing platforms.

Location
Scandic Gothenburg Central, Gothenburg, Sweden

Date
26th – 27th June 2025

Attending
Laureline Mahe
Joseph Conroy

Automation, decentralisation, standardisation: a path for personalised medicine manufacture

Thursday 26th June 2025

In this poster session, Laureline Mahe, Head of Applied Science explored how emerging technologies are reshaping the manufacture of personalised cell and gene therapies. The presentation provided insight into:

Integrating automation and process analytical technologies within cell and gene therapy manufacture for reduced costs and improved quality
The value of decentralised manufacture for the production of small-batch personalised therapies
Building confidence in the efficacy of cell and gene manufacture through standardisation.

User-centred design for effective cGMP compliant, automated bioprocessing platforms in cell and gene therapies

Thursday 26th June 2025

In this poster session, Joseph Conroy, Consultant Mechanical Engineer, presented guidance on developing efficient and user-centred designs for automated bioprocessing platforms with strong adoption potential, including:

The importance of user-centred design in the creation of automated bioprocessing platforms to improve regulatory compliance (cGMP/GAMP) and usability for therapy developers, increasing the accessibility of life-saving therapies
Why end users should be involved early on in development to identify common pain points and help shape friction-free workflows that create reliable, cost-effective systems
How well-designed, user-centred platforms support personalised cell and gene therapies that are more accessible and scalable.

Can we support your cell and gene therapy solution?

Our multidisciplinary team bridges science, engineering and user experience to help you develop novel cell and gene therapy solutions that change the face of healthcare.

Contact us to find out more.